The yearly conference brings together leaders throughout the world who are dedicated to advancing treatment options for Alzheimer’s disease (AD). This year, Jim Hendrix presented the LIFE-DSR blood biomarker data at (Clinical Trials in Alzheimer’s Disease) CTAD’s November 2020 digital conference. The LIFE-DSR study is an ongoing natural history study designed to better understand the factories that underlie symptoms of clinical presentation of Down syndrome associated AD (DS-AD). The COVID pandemic provided an opportunity to conduct early analyses on neurodegenerative biomarkers P-tau181, P-tau217 and NfL.[/vc_column][/vc_row][image_with_animation image_url=”6128″ image_size=”full” animation_type=”entrance” animation=”Fade In” hover_animation=”none” alignment=”center” img_link_target=”_blank” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default” img_link=”https://old.lumindidsc.org/wp-content/uploads/2022/07/ctad_poster_life-dsr_biomarker__hendrix_.pdf”][/vc_row]Click on image to download a PDF.
Learn more about the LuMind IDSC Foundation and Eli Lilly and Company partnership.[/vc_column][/vc_row]